Meclizine
Treatment for Vertigo
Typical Dosage: 12.5-50 mg daily, once a day or divided doses
Effectiveness
60%
Safety Score
75%
Clinical Trials
2
Participants
5.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
12.5-50 mg daily, once a day or divided doses
Time to Effect
30-60 minutes
Treatment Duration
Short-term for acute episodes (days), as needed
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$1,000
Side Effect Mgmt:$10
Total Annual:$1,040
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$53.33
Meclizine Outcomes
for Vertigo
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+75%
Common Side Effects
Drowsiness
+25%
Dry mouth
+12%
Blurred vision
+8%
Constipation
+5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Meclizine in Vertigo
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
NCT02112578COMPLETEDPHASE3
292 participants
INTERVENTIONAL
Maringá, Brazil +6 more
Started: Nov 1, 2016
Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients
NCT00641797COMPLETEDNA
26 participants
INTERVENTIONAL
Allentown, United States
Started: Nov 1, 2006